Why is Macrogenics (MGNX) Stock Down 28% Today?

Macrogenics (NASDAQ:MGNX) stock is dropping on Wednesday as the biopharmaceutical company prepares to discontinue a clinical trial of vobramitamab duocarmazine. How This Affects MGNX Stock On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. Scott Koenig, M.D., Ph.D., president and CEO of MacroGeni ...